Barcelona, Spain
Barcelona, Spain

Time filter

Source Type

Callejo J.,University of Barcelona | Salvador C.,University of Barcelona | Gonzalez-Nunez S.,University of Barcelona | Almeida L.,University of Barcelona | And 4 more authors.
Journal of Ovarian Research | Year: 2013

Currently, cryopreservation of oocytes, embryos and ovarian tissue is considered the basis of fertility preservation programs for women with cancer and other diseases who are rendered sterile by gonadotoxic drugs or radiation.Numerous studies have confirmed that autograft of frozen-thawed ovarian tissue can restore ovarian function and fertility. A total of twenty-two live births have been reported but we still have to consider this technique as experimental. The main problem is that the implant undergoes ischemia until neoangiogenesis is restored, resulting in significant follicular loss.At the moment, there are numerous publications in different medical fields that publish successful experiences with plasma rich in platelets (PRP) in different clinical situations promoting angiogenesis. Thus, we considered the possibility of using it in the field of ovarian autologous transplantation in order to improve the vascularization of the implant and its quality. For this, both thawed ovarian tissue as practiced pockets on the rear side of the broad ligament which have been placed, have been impregnated with PRP. We can say that the implant treated in this way has had a rapid and successful response.We report a special interesting case because this is the first time that this technique is performed successfully in a woman without ovaries combined with growth factors to promote neoangiogenesis. Obviously, the results of the hormonal response come exclusively from the implanted tissue in these special conditions. © 2013 Callejo et al.; licensee BioMed Central Ltd.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: NMP-2008-2.3-1 | Award Amount: 3.58M | Year: 2010

Understanding the biological signals and their temporal magnitude involved in the division, maturation and migration of haematopoietic stem cells (HSCs) and their differentiated progeny would allow for a controlled continuous production of mature blood cells. By careful selection of a 3-dimensional micro-environment it is possible to mimic the niche within bone marrow in which haematopoiesis occurs. Further, by design and control of the flow profile within this microenvironment, it is possible to fine tune the rate of departure of the differentiating cells into a separate microenvironment suitable for further maturation, so creating the conditions for the generation of mature blood cells which could be a continuous process. This research will determine the requirements for the control of the fluidic behaviour within bioreactors for the generation of HSC. Complex, composite systems that allow for the temporal and spatial separation of microenvironments allowing for not only variation in the fluid flow and oxygen tension, but a change in the chemical nature of the culture conditions, will provide the opportunity for delivery of controlling factors. The principle is based on the ability to provide nutritional exchange with an overall zero, or very small, net mass transport. Mechanical design will allow us to match the rate of HSC division, providing the opportunity to derive the daughter cells into the correct environment for red blood cell development over an appropriate time frame. Differentiation of HSCs into different blood cell types occurs within different bone marrow niches and so mimicry of the erythrocyte niche is likely to result in maximisation of the rate of red blood cell development.


Fry L.J.,Nottingham Trent University | Querol S.,Banc de Sang I Teixits | Gomez S.G.,Nottingham Trent University | Mcardle S.,Nottingham Trent University | And 2 more authors.
Vox Sanguinis | Year: 2015

Background and Objectives: Advantages of using cord blood (CB) over other sources of haematopoietic progenitor cells, such as bone marrow, include the ability to cryopreserve and bank the samples until requested for a transplant. Cryopreservation requires the addition of a cryoprotectant to prevent the formation of intracellular ice during freezing. Dimethyl sulphoxide (DMSO) is commonly used at a concentration of 10% (v/v); however, there is evidence to suggest this chemical is toxic to cells as well as to patients after infusion. Materials and Methods: The toxic effects of DMSO were assessed through cell viability and in vitro functional assays in fresh and post-thaw CB samples before determining the maximum exposure time and optimal concentration for cryopreservation. Results: A dose-dependent toxicity of DMSO was observed in fresh samples with 40% removing all viable and functional haematopoietic progenitor cells (HPC). In fresh and post-thaw analysis, minimal toxic effect was observed when cryopreservation was delayed for up to 1 h after 10% DMSO addition. After thawing, DMSO washout was superior to dilution or unmanipulated when maintained for long periods (advantage observed 1 h after thawing). Finally, the optimum concentration for cryopreserving CB was found to be 7·5 to 10% with detrimental effects observed outside of this range. Conclusion: These results support the use of 7·5-10% as the optimal DMSO concentration and the maximum exposure time should be limited to <1 h prior to freezing and 30 min post-thaw. © 2015 International Society of Blood Transfusion.


Grasas A.,University Pompeu Fabra | Bosch M.-A.,Banc de Sang I Teixits | Ortiz P.,Banc de Sang I Teixits | Puig L.,Banc de Sang I Teixits
Vox Sanguinis | Year: 2015

Recent studies suggest that transfusion of old red blood cell (RBC)s, mainly those close to the 42-day maximum shelf life (MSL), is associated with increased morbi-mortality. Although there is no formal proof supporting a causal relationship, the precautionary principle asks for corrective interventions whenever they do not bring about other risks or unjustified costs. Here, we investigated the feasibility of reducing the MSL. Materials and Methods: A trace simulation model was used to analyse the repercussions of several MSLs on a large regional blood system. The baseline model was fed with real input and output data from years 2009 to 2010 and validated against real inventory data. Shortage and outdate rates and inventory levels for each blood group were derived assuming 42-, 35-, 28-, 21- and 14-day MSLs, as well as several distribution rules and supply shocks (periods without blood collections). Results: The model shows that MSL could be reduced to 28-35 days without major increases in the shortage or outdate rates, even after supply shocks. At the 21-day MSL, the inventory capability to compensate supply shocks was severely reduced and translated into large shortage rates. The later were higher for group O and Rh-negative RBCs as compared to group A and Rh-positive, respectively. Conclusion: Reductions of MSL to 28-35 days seem feasible and riskless and do not require major changes in the inventory management policies. Consequently, and giving preponderance to the precautionary principle, the Catalan Blood Agency has decided to reduce the MSL of RBCs from 42 to 35 days. © 2014 International Society of Blood Transfusion.


Garcia J.,Banc de Sang i Teixits
Transfusion and Apheresis Science | Year: 2010

Today Cord Blood (CB) Transplants are accepted as a therapeutic resource for the treatment of a variety of disorders, comparing in some cases, with transplants performed with other sources of progenitors. Unrelated Cord Blood Banks (CBBs) have significantly contributed to this improvement by the improvement on the knowledge of the CB biology and technical developments. Today, there are more than 100 active Cord Blood Banks (CBB), with an inventory of more than 400,000 units, which have generated more than 10000 cord blood transplants all around the world. Access to the world-wide CB inventory, as well as the hemopoietic progenitors inventory from adult donors, is a rather complex task which is continuously subject to improvements and consolidations. The growing numbers of CBBs and the search for efficiency has driven them to constitute or adapt consolidated data bases and access systems, and to develop a number of registries or networks to improvedthe access to inventories. The purpose of the present article is to provide a general overview on the number of CB units stored around the word, the quality accreditation systems and how the CB networks and their national and international inventories and registries are organized in order to support the, every time more efficient search for suitable CB units for patients lacking family donors. © 2010.


Procedure for the undifferentiated or myeloid lineage biased expansion of haematopoietic stem cells coming from umbilical cord blood, mobilized peripheral blood or bone marrow. Procedure for the undifferentiated or myeloid lineage biased expansion of haematopoietic stem cells (HSCs). More specifically, the present invention relates to a procedure of expansion of HSCs from umbilical cord blood, bone marrow or mobilized peripheral blood. Said procedure comprises the steps of expansion culturing of the purified CD34+ cells at constant volume, expansion culturing of said cells at variable volume and the conditioning of the CD34+ cells for transplantation. With this procedure the dose of undifferentiated or myeloid lineage biased HSCs which is necessary for their clinical use is produced reproducibly, robustly and safely.


Procedure for the undifferentiated or myeloid lineage biased expansion of haematopoietic stem cells coming from umbilical cord blood, mobilized peripheral blood or bone marrow. Procedure for the undifferentiated or myeloid lineage biased expansion of haematopoietic stem cells (HSCs). More specifically, the present invention relates to a procedure of expansion of HSCs from umbilical cord blood, bone marrow or mobilized peripheral blood. Said procedure comprises the steps of expansion culturing of the purified CD34+ cells at constant volume, expansion culturing of said cells at variable volume and the conditioning of the CD34+ cells for transplantation. With this procedure the dose of undifferentiated or myeloid lineage biased HSCs which is necessary for their clinical use is produced reproducibly, robustly and safely.


The present invention relates to a method for obtaining a tissue engineering product designed to regenerate cartilage tissue, said product comprising expanded bone marrow mesenchymal cells, a non-cellular matrix and a fibrin gel, the method comprising the steps of: (a) expanding the mesenchymal cells; (b) conjugating the mesenchymal cells to the matrix; (c) washing the product obtained in step (b); and (d) mixing the product obtained in step (c) with a fibrin gel.


This invention relates to a procedure for preparing a tissue engineering product for the regeneration of bone tissues. More particularly this invention relates to a product which mainly comprises expanded mesenchymal cells of bone origin immobilised on bone supports and combined with fibrin gels. The said procedure fundamentally comprises the stages of colonising the bone supports and combining the colonised particles through fibrin gels.


Patent
Banc De Sang I Teixits | Date: 2010-06-11

The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants.

Loading Banc de Sang I Teixits collaborators
Loading Banc de Sang I Teixits collaborators